The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance
Open accessAbstract
The emergence and spread of carbapenem-resistant Gram-negative pathogens is a global public health problem. The acquisition of metallo-β-lactamases (MBLs) such as NDM-1 is a principle contributor to the emergence of carbapenem-resistant Gram-negative pathogens that threatens the use of penicillin, cephalosporin and carbapenem antibiotics to treat infections. To date, a clinical inhibitor of MBLs that could reverse resistance and re-sensitize resistant Gram-negative pathogens to carbapenems has not been found. Here we have identified a fungal natural product, aspergillomarasmine A (AMA), that is a rapid and potent inhibitor of the NDM-1 enzyme and another clinically relevant MBL, VIM-2. AMA also fully restored the activity of meropenem against Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp. possessing either VIM or NDM-type alleles. In mice infected with NDM-1-expressing Klebsiella pneumoniae, AMA efficiently restored meropenem activity, demonstrating that a combination of AMA and a carbapenem antibiotic has therapeutic potential to address the clinical challenge of MBL-positive carbapenem-resistant Gram-negative pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SignalP 4.0: discriminating signal peptides from transmembrane regions
Petersen, T. N., Brunak, S., von Heijne, G., & Nielsen, H. (2011) · Nature Methods · doi:10.1038/nmeth.1701 · Cited by 8,847
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., & Tenover, F. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1151-1161.2001 · Cited by 1,639
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
A continuous spectrophotometric assay for angiotensin converting enzyme
Holmquist, B., Bünning, P., & Riordan, J. F. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90769-3 · Cited by 406
Proliferation and significance of clinically relevant β‐lactamases
Bush, K. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12023 · Cited by 337
New Delhi Metallo-β-Lactamase: Structural Insights into β-Lactam Recognition and Inhibition
King, D. T., Worrall, L. J., Gruninger, R., & Strynadka, N. C. J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303579d · Cited by 297
Self-citation
Cited by
CARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database
Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz935 · Cited by 3,202
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Self-citationAntimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Self-citationThe Science of Antibiotic Discovery
Lewis, K. (2020) · Cell · doi:10.1016/j.cell.2020.02.056 · Cited by 797
A new antibiotic selectively kills Gram-negative pathogens
Imai, Y., Meyer, K. J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S., Caboni, M., Mori, M., Niles, S., Ghiglieri, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1791-1 · Cited by 743
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., & Zong, Z. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-18 · Cited by 700
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
Wright, G. D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.009 · Cited by 604
Self-citationA broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens
Song, M., Liu, Y., Huang, X., Ding, S., Wang, Y., Shen, J., & Zhu, K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0723-z · Cited by 484
Molecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Frisvad, J. C., Møller, L. L. H., Larsen, T. O., Kumar, R., & Arnau, J. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9354-1 · Cited by 380
Antibiotic resistance breakers: current approaches and future directions
Laws, M., Shaaban, A., & Rahman, K. M. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz014 · Cited by 356
Opportunities for natural products in 21st century antibiotic discovery
Wright, G. D. (2017) · Natural Product Reports · doi:10.1039/c7np00019g · Cited by 343
Self-citationAntibiotic Adjuvants: Diverse Strategies for Controlling Drug‐Resistant Pathogens
Gill, E. E., Franco, O. L., & Hancock, R. E. W. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12478 · Cited by 319
Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00397-20 · Cited by 315
Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling
Culp, E. J., Waglechner, N., Wang, W., Fiebig-Comyn, A. A., Hsu, Y.-P., Koteva, K., Sychantha, D., Coombes, B. K., Van Nieuwenhze, M. S., Brun, Y. V., et al. (2020) · Nature · doi:10.1038/s41586-020-1990-9 · Cited by 290
Self-citationOvercoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics
MacNair, C. R., Stokes, J. M., Carfrae, L. A., Fiebig-Comyn, A. A., Coombes, B. K., Mulvey, M. R., & Brown, E. D. (2018) · Nature Communications · doi:10.1038/s41467-018-02875-z · Cited by 287
Self-citationAntibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Antibiotic Adjuvants: Make Antibiotics Great Again!
Douafer, H., Andrieu, V., Phanstiel, O., & Brunel, J. M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01781 · Cited by 272
Pyruvate cycle increases aminoglycoside efficacy and provides respiratory energy in bacteria
Su, Y.-B., Peng, B., Li, H., Cheng, Z.-X., Zhang, T.-T., Zhu, J.-X., Li, D., Li, M.-Y., Ye, J.-Z., Du, C.-C., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714645115 · Cited by 271
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Bahr, G., González, L. J., & Vila, A. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00138 · Cited by 266
Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Bollenbach, T. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.05.008 · Cited by 261
Robbins, N., Spitzer, M., Wang, W., Waglechner, N., Patel, D. J., O’Brien, J. S., Ejim, L., Ejim, O., Tyers, M., & Wright, G. D. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.08.015 · Cited by 41
Self-citationMount, H. O., Revie, N. M., Todd, R. T., Anstett, K., Collins, C., Costanzo, M., Boone, C., Robbins, N., Selmecki, A., & Cowen, L. E. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007319 · Cited by 34
Metadata
- Authors
- King, A. M., Reid-Yu, S. A., Wang, W., King, D. T., De Pascale, G., Strynadka, N. C., Walsh, T. R., Coombes, B. K., & Wright, G. D.
- Venue
- Nature
- Published
- 2014-06
- Volume
- 510
- Issue
- 7506
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2073060607
- Cited by
- 554
- References
- 20
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.